Actively Recruiting

Phase 4
Age: 35Years - 65Years
All Genders
NCT06093932

Efficacy of Songling Xuemaikang Capsules on Grade 1 Hypertension: a Randomized Controlled Trial

Led by Xiyuan Hospital of China Academy of Chinese Medical Sciences · Updated on 2024-08-20

100

Participants Needed

5

Research Sites

190 weeks

Total Duration

On this page

Sponsors

X

Xiyuan Hospital of China Academy of Chinese Medical Sciences

Lead Sponsor

S

Suzhou Hosptial of Traditional Chinese Medicine

Collaborating Sponsor

AI-Summary

What this Trial Is About

The purpose of this study is: 1. To evaluate the efficacy of Songling Xuemaikang Capsules(SLXMKC) with grade 1 hypertension. 2. To reveal the potiential effects of SLXMKC on vascular function and structure of patients with grade 1 hypertension. 3. To explore the underlying mechanisms of the therapeutic effects of SLXMKC on the intervention of grade 1 hypertension.

CONDITIONS

Official Title

Efficacy of Songling Xuemaikang Capsules on Grade 1 Hypertension: a Randomized Controlled Trial

Who Can Participate

Age: 35Years - 65Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age between 35 and 65 years old, male or female
  • Diagnosed with grade 1 essential hypertension
  • Not currently taking antihypertensive drugs regularly or have taken them irregularly in the past
  • Signed informed consent form
Not Eligible

You will not qualify if you...

  • Significant liver dysfunction (ALT and AST more than twice the normal range)
  • Significant kidney dysfunction (serum creatinine ≥2.0 mg/dl or eGFR <60 ml/min/1.73m2)
  • Gastrointestinal diseases affecting drug absorption
  • Allergy to the study medication
  • Pregnant or breastfeeding women, or men planning to father a child within six months
  • Other serious primary diseases or malignant tumors
  • Hyperlipidemia, regardless of lipid-lowering treatment
  • Presence of left ventricular hypertrophy, ankle-brachial index <0.9, carotid intima-media thickness ≥0.9 mm, or atherosclerotic plaque
  • Hypertension with other serious comorbidities such as cerebrovascular disease, cardiovascular diseases, renal disease, peripheral artery disease, retinopathy, or diabetes
  • Any other serious condition deemed unsuitable for the study

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 5 locations

1

Xiyuan Hospital of China Academy of Chinese Medical Sciences

Beijing, Beijing Municipality, China, 100091

Actively Recruiting

2

Suzhou Hosptial of Traditional Chinese Medicine

Suzhou, Jiangsu, China, 215002

Not Yet Recruiting

3

Affiliated Hospital of Shandong University of Traditional Chinese Medicine

Jinan, Shandong, China, 250013

Not Yet Recruiting

4

China Academy of Chinese Medical Sciences Xiyuan Hospital Jining Hospital

Jining, Shandong, China, 272000

Not Yet Recruiting

5

China Academy of Chinese Medical Sciences Xiyuan Hospital Shanxi Hospital

Taiyuan, Shanxi, China, 030024

Not Yet Recruiting

Loading map...

Research Team

A

Anlu Wang, Doctor

CONTACT

Q

Qiyu Liu, Doctor

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

DOUBLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here